IP Library Granted Patent US 11,754,574
Granted Patent B2
US 11,754,574 · App. 16/500,713 · Granted Sep 12, 2023

Red cell diluent with EDTA and methods for making and using the same

Inventors: Mortimer Alzona (Norcross, GA); Bryan Marshall (Norcross, GA); Elizabeth Cope (Norcross, GA); Margot Borgel (Norcross, GA); Teresa Welch (Norcross, GA)
Assignee: IMMUCOR, INC.
G01N33/80G01N1/38G01N33/5005G01N33/6854
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,754,574
App. No.
16/500,713
Granted
Sep 12, 2023
Kind
B2
Abstract

The present disclosure relates to a red blood cell (RBC) solution comprising ethylenediaminetetraacetic acid (EDTA) and methods for making and using the same. The solution can comprise EDTA at a concentration from 3-5 g/L, including 4 g/L. Well plates prepared using the solution can provide a decreased rate of false positive results in automated immunoassays for detecting RBC antibodies in a patient sample.

Claims (13)

1. A method of preparing a well comprising:

preparing a RBC solution by suspending packed red blood cells (RBCs) in a solution comprising ethylenediaminetetraacetic acid (EDTA); and

applying the RBC solution to a well to allow the RBCs in the RBC solution to attach to the surface of the well, thereby immobilizing RBCs in the well, and

treating the immobilized RBCs with a lysing agent such that fragments of the RBCs remain immobilized in the well.

2. The method of claim 1 , wherein the well comprises an attachment molecule bound to a surface of the well and the RBCs are immobilized in the well by the attachment molecule.

3. The method of claim 1 , further comprising washing the well to remove cellular debris.

4. The method of claim 3 , further comprising treating the well with a drying solution.

5. The method of claim 4 , wherein the well is stored for at least three days following treatment with the drying solution.

6. The method of claim 1 , wherein the treating with the lysing agent is performed at least twenty-four hours after applying the RBC solution to the well.

7. The method claim 1 , wherein the well surface comprises polystyrene.

8. The method claim 1 , wherein the solution comprises EDTA at a concentration from 3-5 g/L.

9. The method of claim 8 , wherein the concentration is 4 g/L.

10. The method of claim 1 , wherein the EDTA is one or more of disodium EDTA and tetrasodium EDTA.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Mar 15, 2023
From: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
To: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.; SIRONA GENOMICS, INC.; IMMUCOR GTI DIAGNOSTICS, INC.
Reel/Frame 063090/0033 →
RELEASE OF SECURITY INTEREST Recorded Mar 15, 2023
From: ALTER DOMUS (US) LLC, AS COLLATERAL AGENT
To: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.; SIRONA GENOMICS, INC.; IMMUCOR GTI DIAGNOSTICS, INC.
Reel/Frame 063090/0111 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2022
From: MORTIMER, ALZONA; BORGEL, MARGOT; WELCH, TERESA; COPE, ELIZABETH; MARSHALL, BRYAN
To: IMMUCOR, INC.
Reel/Frame 059600/0001 →
SECURITY INTEREST Recorded Jul 2, 2020
From: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.; SIRONA GENOMICS, INC.; IMMUCOR GTI DIAGNOSTICS INC.
To: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 053119/0135 →
SECURITY INTEREST Recorded Jul 2, 2020
From: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.; SIRONA GENOMICS, INC.; IMMUCOR GTI DIAGNOSTICS INC.
To: ALTER DOMUS (US) LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 053119/0152 →
Continuity (2)
Provisional Application 62480879 · Apr 3, 2017
Related Publication 20200191806A1 · Jun 18, 2020